Britain: AstraZeneca vaccine reduces coronavirus transmission by 67% from first dose

The vaccine of AstraZeneca and the University of Oxford in the disease Covid-19 reduces by 67% the transmission of the virus from the first dose, according to an analysis of clinical trials.

The analysis confirms the vaccination strategy of the British government . In it, the Oxford study, which should be reviewed by peers before being published, states that not only are people vaccinated protected against the disease, but they are also less likely to transmit the coronavirus to others.

The head of the program, Andrew Pollard, explained to the BBC today that this vaccine could have a “huge impact” on transmission, but that these tests had been performed before the mutations appeared, and that ” this virus is trying to find ways to keep it going . ”

The study shows 76% efficacy against infections after a first dose, which is maintained for three months. Efficacy rises to 82% after a second dose of the vaccine, given three months later.

These data confirm the strategy of the government, which, wanting to proceed with vaccinations more widely, had decided to postpone the second dose for up to 12 weeks in order to vaccinate as many as possible. Two vaccines are currently being used in the country, that of AstraZeneca / Oxford and that of Pfizer / BioNTech, to which the Moderna vaccine will be added in the spring.

“The study unequivocally supports our strategy,” Health Minister Matt Hancock told the BBC. “It shows the world that the Oxford vaccine works well.”

The strategy of the British government, which approved vaccines in December and decided to delay the second dose, has been criticized, especially by France. Unlike the United Kingdom, France and Germany do not recommend giving the vaccine to people under the age of 65, even if the European Medicines Agency has approved it for all adults.

The French Undersecretary of State for European Affairs, Clement Bonn, said the British were “taking a lot of risks in this vaccination campaign”. Prior to its EU approval, French President Emmanuel Macron had expressed doubts about the AstraZeneca vaccine: “Today we believe it is almost ineffective for those over 65 years of age.”

The British government, which has given a first dose to nearly 10 million people, is counting on vaccination to allow a way out of the strict ban in the UK, which has been hit hard by the virus that has cost life there. to more than 108,000 people.

“If these vaccines reduce transmission to the extent that they are said to reduce it, it means that the relaxation of social constraints will be possible sooner than it would be if we had to wait for collective immunity,” said Dr Gillis. Brian-Thier, former president of the School of Pharmaceutical Medicine. “This would be the Holy Grail of global vaccine development,” he added.


Leave a Reply

Your email address will not be published. Required fields are marked *